Cutaneous Melanoma, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology

Restricted access

The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Cutaneous melanoma have been significantly revised over the past few years in response to emerging data on immune checkpoint inhibitor therapies and BRAF-targeted therapy. This article summarizes the data and rationale supporting extensive changes to the recommendations for systemic therapy as adjuvant treatment of resected disease and as treatment of unresectable or distant metastatic disease.

Discussion Section Writing Committee

  • 1.

    Pehamberger H, Soyer HP, Steiner A, . Austrian Malignant Melanoma Cooperative Group Adjuvant interferon alfa-2a treatment in resected primary stage II cutaneous melanoma. J Clin Oncol 1998;16:1425–1429.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 2.

    Grob JJ, Dreno B, de la Salmonière P, . French Cooperative Group on Melanoma Randomised trial of interferon alpha-2a as adjuvant therapy in resected primary melanoma thicker than 1.5 mm without clinically detectable node metastases. Lancet 1998;351:1905–1910.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 3.

    Garbe C, Radny P, Linse R, . Adjuvant low-dose interferon alpha2a with or without dacarbazine compared with surgery alone: a prospective-randomized phase III DeCOG trial in melanoma patients with regional lymph node metastasis. Ann Oncol 2008;19:1195–1201.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 4.

    Hansson J, Aamdal S, Bastholt L, . Nordic Melanoma Cooperative Group Two different durations of adjuvant therapy with intermediate-dose interferon alfa-2b in patients with high-risk melanoma (Nordic IFN trial): a randomised phase 3 trial. Lancet Oncol 2011;12:144–152.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 5.

    Kirkwood JM, Strawderman MH, Ernstoff MS, . Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol 1996;14:7–17.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 6.

    Kirkwood JM, Manola J, Ibrahim J, . Eastern Cooperative Oncology Group A pooled analysis of eastern cooperative oncology group and intergroup trials of adjuvant high-dose interferon for melanoma. Clin Cancer Res 2004;10:1670–1677.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 7.

    Kirkwood JM, Ibrahim JG, Sondak VK, . High- and low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/C9190. J Clin Oncol 2000;18:2444–2458.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 8.

    Kirkwood JM, Ibrahim JG, Sosman JA, . High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: results of intergroup trial E1694/S9512/C509801. J Clin Oncol 2001;19:2370–2380.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 9.

    Eggermont AM, Suciu S, Santinami M, .; EORTC Melanoma Group Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial. Lancet 2008;372:117–126.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 10.

    Cascinelli N, Belli F, MacKie RM, . Effect of long-term adjuvant therapy with interferon alpha-2a in patients with regional node metastases from cutaneous melanoma: a randomised trial. Lancet 2001;358:866–869.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 11.

    Hancock BW, Wheatley K, Harris S, . Adjuvant interferon in high-risk melanoma: the AIM HIGH Study--United Kingdom Coordinating Committee on Cancer Research randomized study of adjuvant low-dose extended-duration interferon Alfa-2a in high-risk resected malignant melanoma. J Clin Oncol 2004;22:53–61.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 12.

    Kleeberg UR, Suciu S, Bröcker EB, . EORTC Melanoma Group in cooperation with the German Cancer Society (DKG) Final results of the EORTC 18871/DKG 80-1 randomised phase III trial. rIFN-alpha2b versus rIFN-gamma versus ISCADOR M versus observation after surgery in melanoma patients with either high-risk primary (thickness >3 mm) or regional lymph node metastasis. Eur J Cancer 2004;40:390–402.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 13.

    Eggermont AM, Suciu S, Rutkowski P, . EORTC Melanoma Group Long term follow up of the EORTC 18952 trial of adjuvant therapy in resected stage IIB-III cutaneous melanoma patients comparing intermediate doses of interferon-alpha-2b (IFN) with observation: Ulceration of primary is key determinant for IFN-sensitivity. Eur J Cancer 2016;55:111–121.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 14.

    McMasters KM, Egger ME, Edwards MJ, . Final eesults of the Sunbelt Melanoma Trial: a multi-institutional prospective randomized phase III study evaluating the role of adjuvant high-dose interferon alfa-2b and completion lymph node dissection for patients staged by sentinel lymph node biopsy. J Clin Oncol 2016;34:1079–1086.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 15.

    Agarwala SS, Lee SJ, Yip W, . Phase III randomized study of 4 weeks of high-dose interferon-α-2b in stage T2bNO, T3a-bNO, T4a-bNO, and T1-4N1a-2a (microscopic) melanoma: a trial of the Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Cancer Research Group (E1697). J Clin Oncol 2017;35:885–892.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 16.

    Creagan ET, Dalton RJ, Ahmann DL, . Randomized, surgical adjuvant clinical trial of recombinant interferon alfa-2a in selected patients with malignant melanoma. J Clin Oncol 1995;13:2776–2783.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 17.

    Eggermont AM, Suciu S, Testori A, . Long-term results of the randomized phase III trial EORTC 18991 of adjuvant therapy with pegylated interferon alfa-2b versus observation in resected stage III melanoma. J Clin Oncol 2012;30:3810–3818.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 18.

    Ives NJ, Suciu S, Eggermont AMM, . International Melanoma Meta-Analysis Collaborative Group (IMMCG) Adjuvant interferon-α for the treatment of high-risk melanoma: An individual patient data meta-analysis. Eur J Cancer 2017;82:171–183.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 19.

    Eggermont AM, Chiarion-Sileni V, Grob JJ, . Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial. Lancet Oncol 2015;16:522–530.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 20.

    Eggermont AM, Chiarion-Sileni V, Grob JJ, . Prolonged survival in stage III melanoma with ipilimumab adjuvant therapy. N Engl J Med 2016;375:1845–1855.

  • 21.

    Weber J, Mandala M, Del Vecchio M, . CheckMate 238 Collaborators Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma. N Engl J Med 2017;377:1824–1835.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 22.

    Eggermont AMM, Blank CU, Mandala M, . Adjuvant pembrolizumab versus placebo in resected stage III melanoma. N Engl J Med 2018;378:1789–1801.

  • 23.

    Long GV, Hauschild A, Santinami M, . Adjuvant dabrafenib plus trametinib in stage III BRAF-mutated melanoma. N Engl J Med 2017;377:1813–1823.

  • 24.

    Flaherty LE, Othus M, Atkins MB, . Southwest Oncology Group S0008: a phase III trial of high-dose interferon Alfa-2b versus cisplatin, vinblastine, and dacarbazine, plus interleukin-2 and interferon in patients with high-risk melanoma--an intergroup study of cancer and leukemia Group B, Children’s Oncology Group, Eastern Cooperative Oncology Group, and Southwest Oncology Group. J Clin Oncol 2014;32:3771–3778.

    • Search Google Scholar
    • Export Citation
  • 25.

    Gershenwald JE, Scolyer RA, Hess KR, . Melanoma staging: evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual. CA Cancer J Clin 2017;67:472–492. Available at: https://www.ncbi.nlm.nih.gov/pubmed/29028110.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 26.

    Faries MB, Thompson JF, Cochran AJ, . Completion dissection or observation for sentinel-node metastasis in melanoma. N Engl J Med 2017;376:2211–2222.

  • 27.

    Leiter U, Stadler R, Mauch C, . German Dermatologic Cooperative Oncology Group (DeCOG) Complete lymph node dissection versus no dissection in patients with sentinel lymph node biopsy positive melanoma (DeCOG-SLT): a multicentre, randomised, phase 3 trial. Lancet Oncol 2016;17:757–767.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 28.

    Hodi FS, O’Day SJ, McDermott DF, . Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010;363:711–723.

  • 29.

    Robert C, Thomas L, Bondarenko I, . Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 2011;364:2517–2526.

  • 30.

    Margolin K, Ernstoff MS, Hamid O, . Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial. Lancet Oncol 2012;13:459–465.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 31.

    Ribas A, Hamid O, Daud A, . Association of pembrolizumab with tumor response and survival among patients with advanced melanoma. JAMA 2016;315:1600–1609.

  • 32.

    Ribas A, Puzanov I, Dummer R, . Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial. Lancet Oncol 2015;16:908–918.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 33.

    Robert C, Schachter J, Long GV, .; KEYNOTE-006 investigators Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med 2015;372:2521–2532.

  • 34.

    Larkin J, Chiarion-Sileni V, Gonzalez R, . Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med 2015;373:23–34.

  • 35.

    Hodi FS, Chesney J, Pavlick AC, . Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial. Lancet Oncol 2016;17:1558–1568.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 36.

    Larkin J, Minor D, D’Angelo S, . Overall survival in patients with advanced melanoma who received nivolumab versus investigator’s choice chemotherapy in CheckMate 037: a randomized, controlled, open-label phase III trial. J Clin Oncol 2018;36:383–390.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 37.

    Chapman PB, Hauschild A, Robert C, . BRIM-3 Study Group Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011;364:2507–2516.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 38.

    McArthur GA, Chapman PB, Robert C, . Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study. Lancet Oncol 2014;15:323–332.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 39.

    Long GV, Stroyakovskiy D, Gogas H, . Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial. Lancet 2015;386:444–451.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 40.

    Robert C, Karaszewska B, Schachter J, . Improved overall survival in melanoma with combined dabrafenib and trametinib. N Engl J Med 2015;372:30–39.

  • 41.

    Hauschild A, Grob JJ, Demidov LV, . Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet 2012;380:358–365.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 42.

    Hauschild A, Grob JJ, Demidov LV, . An update on BREAK-3, a phase III, randomized trial: Dabrafenib (DAB) versus dacarbazine (DTIC) in patients with BRAF V600E-positive mutation metastatic melanoma (MM). ASCO Meeting Abstracts 2013;31:9013. Available at: http://meeting.ascopubs.org/cgi/content/abstract/31/15_suppl/9013. Accessed March 12, 2019.

    • Search Google Scholar
    • Export Citation
  • 43.

    Larkin J, Ascierto PA, Dréno B, . Combined vemurafenib and cobimetinib in BRAF-mutated melanoma. N Engl J Med 2014;371:1867–1876.

  • 44.

    Maio M, Lewis K, Demidov L, . BRIM8 Investigators Adjuvant vemurafenib in resected, BRAFV600 mutation-positive melanoma (BRIM8): a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial. Lancet Oncol 2018;19:510–520.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 45.

    Squibb ER, Sons LLC. Prescribing information: YERVOY® (ipilimumab) injection, for intravenous use. 2018. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/125377s096lbl.pdf. Accessed Oct 15, 2018.

  • 46.

    Feng Y, Roy A, Masson E, . Exposure-response relationships of the efficacy and safety of ipilimumab in patients with advanced melanoma. Clin Cancer Res 2013;19:3977–3986.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 47.

    Bertrand A, Kostine M, Barnetche T, . Immune related adverse events associated with anti-CTLA-4 antibodies: systematic review and meta-analysis. BMC Med 2015;13:211.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 48.

    Wolchok JD, Weber JS, Hamid O, . Ipilimumab efficacy and safety in patients with advanced melanoma: a retrospective analysis of HLA subtype from four trials. Cancer Immun 2010;10:9.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 49.

    Wolchok JD, Neyns B, Linette G, . Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study. Lancet Oncol 2010;11:155–164.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 50.

    Tarhini AA, Lee SJ, Hodi FS, . A phase III randomized study of adjuvant ipilimumab (3 or 10 mg/kg) versus high-dose interferon alfa-2b for resected high-risk melanoma (U.S. Intergroup E1609): Preliminary safety and efficacy of the ipilimumab arms (abstract). J Clin Oncol 2017;35:Abstr 9500. Available at: http://ascopubs.org/doi/abs/10.1200/JCO.2017.35.15_suppl.9500. Accessed March 12, 2019.

  • 51.

    Woo SR, Turnis ME, Goldberg MV, . Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape. Cancer Res 2012;72:917–927.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 52.

    Wang C, Thudium KB, Han M, . In vitro characterization of the anti-PD-1 antibody nivolumab, BMS-936558, and in vivo toxicology in non-human primates. Cancer Immunol Res 2014;2:846–856.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 53.

    Bristol-Myers Squibb Company. Prescribing information: OPDIVO (nivolumab) injection, for intravenous use. 2019. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/125554s072lbl.pdf. Accessed Feb 2019.

  • 54.

    Wolchok JD, Chiarion-Sileni V, Gonzalez R, . Overall survival with combined nivolumab and ipilimumab in advanced melanoma. N Engl J Med 2017;377:1345–1356.

  • 55.

    Schachter J, Ribas A, Long GV, . Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006). Lancet 2017;390:1853–1862.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 56.

    Amaria RN, Prieto PA, Tetzlaff MT, . Neoadjuvant plus adjuvant dabrafenib and trametinib versus standard of care in patients with high-risk, surgically resectable melanoma: a single-centre, open-label, randomised, phase 2 trial. Lancet Oncol 2018;19:181–193.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 57.

    Blank CU, Rozeman EA, Fanchi LF, . Neoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma. Nat Med 2018. Available at: https://www.ncbi.nlm.nih.gov/pubmed/30297911. Accessed March 12, 2019. https://doi.org/10.1038/s41591-018-0198-0

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 58.

    Amaria RN, Reddy SM, Tawbi HA, . Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma. Nat Med 2018. Available at: https://www.ncbi.nlm.nih.gov/pubmed/30297909. Accessed March 12, 2019. https://doi.org/10.1038/s41591-018-0197-1

    • Search Google Scholar
    • Export Citation
  • 59.

    Tarhini AA, Edington H, Butterfield LH, . Immune monitoring of the circulation and the tumor microenvironment in patients with regionally advanced melanoma receiving neoadjuvant ipilimumab. PLoS One 2014;9:e87705.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 60.

    Retseck J, VanderWeele R, Lin HM, . Phenotypic and functional testing of circulating regulatory T cells in advanced melanoma patients treated with neoadjuvant ipilimumab. J Immunother Cancer 2016;4:38.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 61.

    Tarhini AA, Zahoor H, Lin Y, . Baseline circulating IL-17 predicts toxicity while TGF-β1 and IL-10 are prognostic of relapse in ipilimumab neoadjuvant therapy of melanoma. J Immunother Cancer 2015;3:39.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 62.

    Weber JS, D’Angelo SP, Minor D, . Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol 2015;16:375–384.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 63.

    Andtbacka RH, Kaufman HL, Collichio F, . Talimogene laherparepvec improves durable response rate in patients with advanced melanoma. J Clin Oncol 2015;33:2780–2788.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 64.

    Long GV, Stroyakovskiy D, Gogas H, . Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma. N Engl J Med 2014;371:1877–1888.

  • 65.

    Larkin J, Del Vecchio M, Ascierto PA, . Vemurafenib in patients with BRAF(V600) mutated metastatic melanoma: an open-label, multicentre, safety study. Lancet Oncol 2014;15:436–444.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 66.

    Robert C, Long GV, Brady B, . Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med 2015;372:320–330.

  • 67.

    Johnson DB, Flaherty KT, Weber JS, . Combined BRAF (dabrafenib) and MEK inhibition (trametinib) in patients with BRAFV600-mutant melanoma experiencing progression with single-agent BRAF inhibitor. J Clin Oncol 2014;32:3697–3704.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 68.

    Postow MA, Chesney J, Pavlick AC, . Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N Engl J Med 2015;372:2006–2017.

  • 69.

    Hamid O, Puzanov I, Dummer R, . Final analysis of a randomised trial comparing pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory advanced melanoma. Eur J Cancer 2017;86:37–45.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 70.

    Ascierto PA, Long GV, Robert C, . Survival outcomes in patients with previously untreated BRAF wild-type advanced melanoma treated with nivolumab therapy: three-year follow-up of a randomized phase 3 trial. JAMA Oncol 2018. Available at: https://www.ncbi.nlm.nih.gov/pubmed/30422243. Accessed March 12, 2019.

  • 71.

    Hodi FS, Chiarion-Sileni V, Gonzalez R, . Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial. Lancet Oncol 2018;19:1480–1492.

    • Crossref
    • Export Citation
  • 72.

    Finn OJ Immuno-oncology: understanding the function and dysfunction of the immune system in cancer. Ann Oncol 2012;23 Suppl 8:viii6-9. Available at: http://www.ncbi.nlm.nih.gov/pubmed/22918931. https://doi.org/10.1093/annonc/mds256

    • Crossref
    • Export Citation
  • 73.

    Bhatia A, Kumar Y. Cellular and molecular mechanisms in cancer immune escape: a comprehensive review. Expert Rev Clin Immunol 2014;10:41–62.

  • 74.

    Vinay DS, Ryan EP, Pawelec G, . Immune evasion in cancer: mechanistic basis and therapeutic strategies. Semin Cancer Biol 2015;35(Suppl):S185–S198.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 75.

    Krummel MF, Allison JP. CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation. J Exp Med 1995;182:459–465.

  • 76.

    Pardoll DM The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 2012;12:252–264.

  • 77.

    Huard B, Prigent P, Tournier M, . CD4/major histocompatibility complex class II interaction analyzed with CD4- and lymphocyte activation gene-3 (LAG-3)-Ig fusion proteins. Eur J Immunol 1995;25:2718–2721.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 78.

    Grosso JF, Kelleher CC, Harris TJ, . LAG-3 regulates CD8+ T cell accumulation and effector function in murine self- and tumor-tolerance systems. J Clin Invest 2007;117:3383–3392.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 79.

    Peggs KS, Quezada SA, Chambers CA, . Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti-CTLA-4 antibodies. J Exp Med 2009;206:1717–1725.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 80.

    Maio M, Grob JJ, Aamdal S, . Five-year survival rates for treatment-naive patients with advanced melanoma who received ipilimumab plus dacarbazine in a phase III trial. J Clin Oncol 2015;33:1191–1196.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 81.

    Wolchok JD, Weber JS, Maio M, . Four-year survival rates for patients with metastatic melanoma who received ipilimumab in phase II clinical trials. Ann Oncol 2013;24:2174–2180.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 82.

    Lebbé C, Weber JS, Maio M, . Survival follow-up and ipilimumab retreatment of patients with advanced melanoma who received ipilimumab in prior phase II studies. Ann Oncol 2014;25:2277–2284.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 83.

    Schadendorf D, Hodi FS, Robert C, . Pooled analysis of long-term survival data from phase II and phase III trials of ipilimumab in unresectable or metastatic melanoma. J Clin Oncol 2015;33:1889–1894.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 84.

    Ascierto PA, Del Vecchio M, Robert C, . Ipilimumab 10 mg/kg versus ipilimumab 3 mg/kg in patients with unresectable or metastatic melanoma: a randomised, double-blind, multicentre, phase 3 trial. Lancet Oncol 2017. Available at: https://www.ncbi.nlm.nih.gov/pubmed/28359784.

    • Crossref
    • Export Citation
  • 85.

    Robert C, Schadendorf D, Messina M, . MDX010-20 investigators Efficacy and safety of retreatment with ipilimumab in patients with pretreated advanced melanoma who progressed after initially achieving disease control. Clin Cancer Res 2013;19:2232–2239.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 86.

    Topalian SL, Drake CG, Pardoll DM. Immune checkpoint blockade: a common denominator approach to cancer therapy. Cancer Cell 2015;27:450–461.

  • 87.

    Schadendorf D, Dummer R, Hauschild A, . Health-related quality of life in the randomised KEYNOTE-002 study of pembrolizumab versus chemotherapy in patients with ipilimumab-refractory melanoma. Eur J Cancer 2016;67:46–54.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 88.

    Robert C, Long GV, Schachter J, . Long-term outcomes in patients (pts) with ipilimumab (ipi)-naive advanced melanoma in the phase 3 KEYNOTE-006 study who completed pembrolizumab (pembro) treatment. J Clin Oncol 2017;35(15_suppl):9504.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 89.

    Carlino MS, Long GV, Schadendorf D, . Outcomes by line of therapy and programmed death ligand 1 expression in patients with advanced melanoma treated with pembrolizumab or ipilimumab in KEYNOTE-006: a randomised clinical trial. Eur J Cancer 2018;101:236–243.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 90.

    Robert C, Ribas A, Wolchok JD, . Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial. Lancet 2014;384:1109–1117.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 91.

    Robert C, Ribas A, Hamid O, . Durable complete response after discontinuation of pembrolizumab in patients with metastatic melanoma. J Clin Oncol 2018;36:1668–1674.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 92.

    Weber JS, Gibney G, Sullivan RJ, . Sequential administration of nivolumab and ipilimumab with a planned switch in patients with advanced melanoma (CheckMate 064): an open-label, randomised, phase 2 trial. Lancet Oncol 2016;17:943–955.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 93.

    Wolchok JD, Kluger H, Callahan MK, . Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med 2013;369:122–133.

  • 94.

    Callahan MK, Kluger H, Postow MA, . Nivolumab plus ipilimumab in patients with advanced melanoma: updated survival, response, and safety data in a phase I dose-escalation study. J Clin Oncol 2018;36:391–398.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 95.

    Di Giacomo AM, Annesi D, Ascierto PA, . A randomized, phase III study of fotemustine versus the combination of fotemustine and ipilimumab or the combination of ipilimumab and nivolumab in patients with metastatic melanoma with brain metastasis: the NIBIT-M2 trial. ASCO Meeting Abstracts 2015;33:TPS9090. Available at: http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/TPS9090.

  • 96.

    Tawbi HA, Forsyth PA, Algazi A, . Combined nivolumab and ipilimumab in melanoma metastatic to the brain. N Engl J Med 2018;379:722–730.

  • 97.

    Long GV, Atkinson V, Lo S, . Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study. Lancet Oncol 2018;19:672–681.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 98.

    Long GV, Atkinson V, Cebon JS, . Standard-dose pembrolizumab in combination with reduced-dose ipilimumab for patients with advanced melanoma (KEYNOTE-029): an open-label, phase 1b trial. Lancet Oncol 2017;18:1202–1210.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 99.

    Hodi FS, Postow MA, Chesney JA, . Clinical response, progression-free survival (PFS), and safety in patients (pts) with advanced melanoma (MEL) receiving nivolumab (NIVO) combined with ipilimumab (IPI) vs IPI monotherapy in CheckMate 069 study. ASCO Meeting Abstracts 2015;33:9004. Available at: http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/9004.

    • Crossref
    • Export Citation
  • 100.

    Schadendorf D, Wolchok JD, Hodi FS, . Efficacy and safety outcomes in patients with advanced melanoma who discontinued treatment with nivolumab and ipilimumab because of adverse events: a pooled analysis of randomized phase II and III trials. J Clin Oncol 2017;35:3807–3814.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 101.

    Olson D, Luke JJ, Hallmeyer S, . Phase II trial of pembrolizumab (pembro) plus 1 mg/kg ipilimumab (ipi) immediately following progression on anti-PD-1 Ab in melanoma (mel) (abstract). 2018;36:Abs 9514. Available at: http://ascopubs.org/doi/abs/10.1200/JCO.2018.36.15_suppl.9514.

    • Crossref
    • Export Citation
  • 102.

    Lebbé C, Meyer N, Mortier L, . Initial results from a phase IIIb/IV study evaluating two dosing regimens of nivolumab (NIVO) in combination with ipilimumab (IPI) in patients with advanced melanoma (CheckMate 511) [abstract]. Ann Oncol 2018;29(suppl_8):LBA47.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 103.

    Puzanov I, Dummer R, Schachter J, . Efficacy based on tumor PD-L1 expression in KEYNOTE-002, a randomized comparison of pembrolizumab (pembro; MK-3475) versus chemotherapy in patients (pts) with ipilimumab-refractory (IPI-R) advanced melanoma (MEL). ASCO Meeting Abstracts 2015;33:3012. Available at: http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/3012.

    • Crossref
    • Export Citation
  • 104.

    Daud AI, Wolchok JD, Robert C, . Programmed death-ligand 1 expression and response to the anti-programmed death 1 antibody pembrolizumab in melanoma. J Clin Oncol 2016;34:4102–4109.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 105.

    Shreders A, Joseph R, Peng C, . Prolonged benefit from ipilimumab correlates with improved outcomes from subsequent pembrolizumab. Cancer Immunol Res 2016;4:569–573.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 106.

    Agrawal S, Feng Y, Roy A, . Nivolumab dose selection: challenges, opportunities, and lessons learned for cancer immunotherapy. J Immunother Cancer 2016;4:72.

  • 107.

    Topalian SL, Sznol M, McDermott DF, . Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol 2014;32:1020–1030.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 108.

    Weber JS, Kudchadkar RR, Yu B, . Safety, efficacy, and biomarkers of nivolumab with vaccine in ipilimumab-refractory or -naive melanoma. J Clin Oncol 2013;31:4311–4318.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 109.

    Freeman-Keller M, Kim Y, Cronin H, . Nivolumab in resected and unresectable metastatic melanoma: characteristics of immune-related adverse events and association with outcomes. Clin Cancer Res 2016;22:886–894.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 110.

    Zhao X, Suryawanshi S, Hruska M, . Assessment of nivolumab benefit-risk profile of a 240-mg flat dose relative to a 3-mg/kg dosing regimen in patients with advanced tumors. Ann Oncol 2017;28:2002–2008.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 111.

    Long GV, Tykodi SS, Schneider JG, . Assessment of nivolumab exposure and clinical safety of 480 mg every 4 weeks flat-dosing schedule in patients with cancer. Ann Oncol 2018. Available at: https://www.ncbi.nlm.nih.gov/pubmed/30215677. https://doi.org/10.1093/annonc/mdy408

    • Crossref
    • Export Citation
  • 112.

    Wang X, Feng Y, Bajaj G, . Quantitative characterization of the exposure-response relationship for cancer immunotherapy: a case study of nivolumab in patients with advanced melanoma. CPT Pharmacometrics Syst Pharmacol 2017;6:40–48.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 113.

    Larkin J, Lao CD, Urba WJ, . Efficacy and safety of nivolumab in patients with BRAF V600 mutant and BRAF wild-type advanced melanoma: a pooled analysis of 4 clinical trials. JAMA Oncol 2015;1:433–440.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 114.

    Freshwater T, Kondic A, Ahamadi M, . Evaluation of dosing strategy for pembrolizumab for oncology indications. J Immunother Cancer 2017;5:43.

  • 115.

    Bajaj G, Wang X, Agrawal S, . Model-based population pharmacokinetic analysis of nivolumab in patients with solid tumors. CPT Pharmacometrics Syst Pharmacol 2017;6:58–66.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 116.

    Merck & Co Inc. Prescribing information: KEYTRUDA® (pembrolizumab) injection, for intravenous use. 2019. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/125514s040lbl.pdf. Accessed Feb 19, 2019.

  • 117.

    Long GV, Schachter J, Ribas A, . 4-year survival and outcomes after cessation of pembrolizumab (pembro) after 2-years in patients (pts) with ipilimumab (ipi)-naive advanced melanoma in KEYNOTE-006 (abstract). J Clin Oncol 2018;36:abstr 9503. Available at: https://meetinglibrary.asco.org/record/159075/abstract. Accessed March 12, 2019.

  • 118.

    Hodi FS, Hwu WJ, Kefford R, . Evaluation of immune-related response criteria and RECIST v1.1 in patients with advanced melanoma treated with pembrolizumab. J Clin Oncol 2016;34:1510–1517.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 119.

    Long GV, Weber JS, Larkin J, . Nivolumab for patients with advanced melanoma treated beyond progression: analysis of 2 phase 3 clinical trials. JAMA Oncol 2017;3:1511–1519.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 120.

    Beaver JA, Hazarika M, Mulkey F, . Patients with melanoma treated with an anti-PD-1 antibody beyond RECIST progression: a US Food and Drug Administration pooled analysis. Lancet Oncol 2018;19:229–239.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 121.

    Wang DY, Salem JE, Cohen JV, . Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis. JAMA Oncol 2018;4:1721–1728.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 122.

    Weber JS, Hodi FS, Wolchok JD, . Safety profile of nivolumab monotherapy: a pooled analysis of patients with advanced melanoma. J Clin Oncol 2017;35:785–792.

  • 123.

    Sznol M, Ferrucci PF, Hogg D, . Pooled analysis safety profile of nivolumab and ipilimumab combination therapy in patients with advanced melanoma. J Clin Oncol 2017;35:3815–3822.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 124.

    Davies H, Bignell GR, Cox C, . Mutations of the BRAF gene in human cancer. Nature 2002;417:949–954.

  • 125.

    Long GV, Menzies AM, Nagrial AM, . Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma. J Clin Oncol 2011;29:1239–1246.

  • 126.

    Dhillon AS, Hagan S, Rath O, . MAP kinase signalling pathways in cancer. Oncogene 2007;26:3279–3290.

  • 127.

    Ekedahl H, Cirenajwis H, Harbst K, . The clinical significance of BRAF and NRAS mutations in a clinic-based metastatic melanoma cohort. Br J Dermatol 2013;169:1049–1055.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 128.

    Sosman JA, Kim KB, Schuchter L, . Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med 2012;366:707–714.

  • 129.

    Blank CU, Larkin J, Arance AM, . Open-label, multicentre safety study of vemurafenib in 3219 patients with BRAFV600 mutation-positive metastatic melanoma: 2-year follow-up data and long-term responders’ analysis. Eur J Cancer 2017;79:176–184.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 130.

    Ascierto PA, Minor D, Ribas A, . Phase II trial (BREAK-2) of the BRAF inhibitor dabrafenib (GSK2118436) in patients with metastatic melanoma. J Clin Oncol 2013;31:3205–3211.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 131.

    Long GV, Eroglu Z, Infante J, . Long-term outcomes in patients with BRAF V600-mutant metastatic melanoma who received dabrafenib combined with trametinib. J Clin Oncol 2018;36:667–673.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 132.

    Ascierto PA, McArthur GA, Dréno B, . Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial. Lancet Oncol 2016;17:1248–1260.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 133.

    Flaherty KT, Robert C, Hersey P, . METRIC Study Group Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med 2012;367:107–114.

  • 134.

    Kim KB, Kefford R, Pavlick AC, . Phase II study of the MEK1/MEK2 inhibitor trametinib in patients with metastatic BRAF-mutant cutaneous melanoma previously treated with or without a BRAF inhibitor. J Clin Oncol 2013;31:482–489.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 135.

    Dummer R, Schadendorf D, Ascierto PA, . Binimetinib versus dacarbazine in patients with advanced NRAS-mutant melanoma (NEMO): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol 2017;18:435–445.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 136.

    Long GV, Flaherty KT, Stroyakovskiy D, . Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study. Ann Oncol 2017;28:1631–1639.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 137.

    Dréno B, Ribas A, Larkin J, . Incidence, course, and management of toxicities associated with cobimetinib in combination with vemurafenib in the coBRIM study. Ann Oncol 2017;28:1137–1144.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 138.

    Dummer R, Ascierto PA, Gogas HJ, . Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol 2018;19:603–615.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 139.

    Dummer R, Ascierto PA, Gogas HJ, . Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol 2018;19:1315–1327.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 140.

    Chapman PB, Robert C, Larkin J, . Vemurafenib in patients with BRAFV600 mutation-positive metastatic melanoma: final overall survival results of the randomized BRIM-3 study. Ann Oncol 2017;28:2581–2587.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 141.

    Ribas A, Gonzalez R, Pavlick A, . Combination of vemurafenib and cobimetinib in patients with advanced BRAF(V600)-mutated melanoma: a phase 1b study. Lancet Oncol 2014;15:954–965.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 142.

    Pavlick AC, Ribas A, Gonzalez R, . Extended follow-up results of phase Ib study (BRIM7) of vemurafenib (VEM) with cobimetinib (COBI) in BRAF-mutant melanoma. ASCO Meeting Abstracts 2015;33:9020. Available at: http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/9020.

    • Crossref
    • Export Citation
  • 143.

    Daud A, Pavlick AC, Ribas A, . Extended follow-up results of a phase 1B study (BRIM7) of cobimetinib (C) and vemurafenib (V) in BRAF-mutant melanoma (abstract). J Clin Oncol 2016;34:Abstr 9510. Available at: http://ascopubs.org/doi/abs/10.1200/JCO.2016.34.15_suppl.9510.

    • Crossref
    • Export Citation
  • 144.

    Chen G, McQuade JL, Panka DJ, . Clinical, molecular, and immune analysis of dabrafenib-trametinib combination treatment for BRAF inhibitor-refractory metastatic melanoma: a phase 2 clinical trial. JAMA Oncol 2016;2:1056–1064.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 145.

    Schreuer M, Jansen Y, Planken S, . Combination of dabrafenib plus trametinib for BRAF and MEK inhibitor pretreated patients with advanced BRAFV600-mutant melanoma: an open-label, single arm, dual-centre, phase 2 clinical trial. Lancet Oncol 2017;18:464–472.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 146.

    Delord JP, Robert C, Nyakas M, . Phase I dose-escalation and -expansion study of the BRAF inhibitor encorafenib (LGX818) in metastatic BRAF-mutant melanoma. Clin Cancer Res 2017;23:5339–5348.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 147.

    de la Cruz-Merino L, Di Guardo L, Grob JJ, . Clinical features of serous retinopathy observed with cobimetinib in patients with BRAF-mutated melanoma treated in the randomized coBRIM study. J Transl Med 2017;15:146.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 148.

    Anker CJ, Grossmann KF, Atkins MB, . Avoiding severe toxicity from combined BRAF inhibitor and radiation treatment: consensus guidelines from the Eastern Cooperative Oncology Group (ECOG). Int J Radiat Oncol Biol Phys 2016;95:632–646.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 149.

    Genentech, Inc. Prescribing information: ZELBORAF® (vemurafenib) tablet for oral use. 2017. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/202429s016lbl.pdf. Accessed Oct 15, 2018.

  • 150.

    GlaxoSmithKline. Prescribing information: TAFINLAR (dabrafenib) capsules, for oral use. 2018. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/202806s010lbl.pdf. Accessed Oct 15, 2018.

  • 151.

    Array BioPharma Inc. Prescribing information: BRAFTOVI (encorafenib) capsules, for oral use. 2018. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210496lbl.pdf. Accessed Oct 15, 2018.

  • 152.

    Genentech, Inc. Prescribing information: COTELLIC (cobimetinib) tablets, for oral use. 2018. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/206192s002lbl.pdf. Accessed Oct 15, 2018.

  • 153.

    GlaxoSmithKline. Prescribing information: MEKINIST (trametinib) tablets, for oral use. 2018. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/204114Orig1s009lbl.pdf. Accessed Oct 15, 2018.

  • 154.

    Array BioPharma Inc. Prescribing information: MEKTOVI (binimetinib) tablets, for oral use. 2018. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210498lbl.pdf. Accessed Oct 15, 2018.

  • 155.

    Smith FO, Downey SG, Klapper JA, . Treatment of metastatic melanoma using interleukin-2 alone or in conjunction with vaccines. Clin Cancer Res 2008;14:5610–5618.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 156.

    Rosenberg SA, Yang JC, Topalian SL, . Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2. JAMA 1994;271:907–913.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 157.

    Atkins MB, Kunkel L, Sznol M, . High-dose recombinant interleukin-2 therapy in patients with metastatic melanoma: long-term survival update. Cancer J Sci Am 2000;6(Suppl 1):S11–S14.

    • Search Google Scholar
    • Export Citation
  • 158.

    Davar D, Ding F, Saul M, . High-dose interleukin-2 (HD IL-2) for advanced melanoma: a single center experience from the University of Pittsburgh Cancer Institute. J Immunother Cancer 2017;5:74.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 159.

    Alva A, Daniels GA, Wong MK, . Contemporary experience with high-dose interleukin-2 therapy and impact on survival in patients with metastatic melanoma and metastatic renal cell carcinoma. Cancer Immunol Immunother 2016;65:1533–1544.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 160.

    Chesney J, Puzanov I, Collichio F, . Randomized, open-label phase II study evaluating the efficacy and safety of talimogene laherparepvec in combination with ipilimumab versus ipilimumab alone in patients with advanced, unresectable melanoma. J Clin Oncol 2018;36:1658–1667.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 161.

    Guo J, Si L, Kong Y, . Phase II, open-label, single-arm trial of imatinib mesylate in patients with metastatic melanoma harboring c-Kit mutation or amplification. J Clin Oncol 2011;29:2904–2909.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 162.

    Carvajal RD, Antonescu CR, Wolchok JD, . KIT as a therapeutic target in metastatic melanoma. JAMA 2011;305:2327–2334.

  • 163.

    Hodi FS, Corless CL, Giobbie-Hurder A, . Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin. J Clin Oncol 2013;31:3182–3190.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 164.

    The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) in partnership with the American Society of Clinical Oncology (ASCO) for Management of Immunotherapy-Related Toxicities (Version 1.2019). © 2018 National Comprehensive Cancer Network, Inc; 2018. Available at: NCCN.org. Accessed Nov 14, 2018. To view the most recent and complete version of the NCCN Guidelines®, go online to NCCN.org.

  • 165.

    Bristol-Myers Squibb Company. BLA 125377 YERVOY (ipilimumab) injection, for intravenous infusion: risk evaluation and mitigation strategy (REMS). 2012. Available at: http://www.fda.gov/downloads/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/UCM249435.pdf. Accessed November 16, 2015.

  • 166.

    Flaherty KT, Infante JR, Daud A, . Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med 2012;367:1694–1703.

All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 14996 14993 1003
PDF Downloads 5283 5283 323
EPUB Downloads 0 0 0